Oncologists' barriers and facilitators for Oncotype Dx use: qualitative study

International Journal of Technology Assessment in Health Care

Volumn 32, Issue 5, 2016, Pages 355-361

  Roberts, Megan C ^a,b   Bryson, Amy ^a   Weinberger, Morris ^a,c   Dusetzina, Stacie B ^a,b,d   Dinan, Michaela A ^e,f   Reeder Hayes, Katherine ^b   Wheeler, Stephanie B ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d UNC Hamner Institute for Drug Safety Sciences   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f DUKE CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Gene expression profiling; Qualitative research

Indexed keywords

CHEMOTHERAPY; DISEASES; GENE EXPRESSION; GENES; PATIENT TREATMENT; TUMORS;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CLINICAL GUIDELINE; CLINICAL PRACTICES; GENE EXPRESSION PROFILING; ORGANIZATIONAL FACTORS; QUALITATIVE RESEARCH; TREATMENT DECISION MAKINGS;

DECISION MAKING;

ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HEALTH BELIEF; HEALTH CARE DISPARITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MALE; MARKETING; MEDICAL DECISION MAKING; MIDDLE AGED; ONCOLOGIST; ONCOTYPE DX; ORGANIZATIONAL STRUCTURE; PATIENT PREFERENCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; QUALITATIVE RESEARCH; SEMI STRUCTURED INTERVIEW; UNITED STATES; ADJUVANT CHEMOTHERAPY; ATTITUDE TO HEALTH; BREAST NEOPLASMS; GENETICS; INTERVIEW; PERSONALIZED MEDICINE; STATISTICS AND NUMERICAL DATA;

TUMOR MARKER;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; ONCOLOGISTS; PRECISION MEDICINE; QUALITATIVE RESEARCH;

EID: 85003837113     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S026646231600060X     Document Type: Article

References (22)

1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726-3734.
3. Sparano JA. TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006; 7: 347-350.
4. Joh JE, Esposito NN, Kiluk JV, et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist. 2011; 16: 1520-1526.
5. Ademuyiwa FO, Miller A, O'Connor T, et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat. 2011; 126: 797-802.
6. Henry LR, Stojadinovic A, Swain SM, et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol. 2009; 99: 319-323.
7. Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: Private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract. 2010; 6: 238-242.
8. Lund MJ, Mosunjac M, Davis KM, et al. 21-Gene recurrence scores: Racial differences in testing, scores, treatment, and outcome. Cancer. 2012; 118: 788-796.
9. Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract. 2013; 9: 182-187.
10. Defrank JT, Salz T, Reeder-Hayes K, Brewer NT. Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics. 2013; 16: 215-222.
11. Albanell J, Gonzalez A, Ruiz-Borrego M, et al. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol. 2012; 23: 625-631.
12. Frambach R, Schillewaert N. Organizational innovation adoption: A multi-level framework of determinants and opportunities for future research. J Bus Res. 2002; 55: 163-176.
13. King N. Template analysis. In: Symon G, Cassell C, eds. Qualitative methods and analysis in organizational research: A practical guide. London: Sage; 1998: 118-134.
14. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312.
15. Wong WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL. The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials. 2012; 33: 1117-1123.
16. Weldon CB, Trosman JR, Gradishar WJ, Benson AB, Schink JC. Barriers to the use of personalized medicine in breast cancer. J Oncol Pract. 2012; 8: e24-e31.
17. Spellman E, Sulayman N, Eggly S, et al. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: Oncologist perspectives. Psychooncology. 2013; 22: 2110-2116.
18. Baumbard Y, Rozmovits L, Tredeau M, et al. The value of personalizing medicine: Medical oncologists? views on gene expression profiling in breast cancer treatment. Oncologist. 2015; 20: 351-356.
19. Roberts MC, Dusetzina S. Utilization and costs for oncotype DX from 2006-2012: Implications for genomic test adoption among private payers. In: AcademyHealth Annual Research Meeting, 2014. San Diego, CA.
20. Brewer NT, Richman AR, DeFrank JT, Reyna VF, Carey LA. Improving communication of breast cancer recurrence risk. Breast Cancer Res Treat. 2012; 133: 553-561.
21. Leggett LE, Lorenzetti DL, Noseworthy T, et al. Experiences and attitudes toward risk of recurrence testing in women with breast cancer: A systematic review. Breast Cancer Res Treat. 2014; 144: 457-465.
22. Dinan MA, Mi X, Reed SD, et al. Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009. JAMA Oncol. 2015; 1: 158-166.